ERBB2 and neoplasm: Eventually, the covalent ZHER2:342‐36FSY‐CR8 ADCN exhibits an outstanding tumor inhibition ratio of 90.03 ± 4.29% in HER2‐positive ovary tumor models, strikingly higher than that of the noncovalent one (64.25 ± 7.71%).